Tonix Pharmaceuticals Holding Corp(TNXP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -12.93 | Insider Own | 0.36% | Shs Outstand | 17.1M | Perf Week | 2.92% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | 34.41% | Insider Trans | 30.46% | Shs Float | 17.1M | Perf Month | -45.79% |
| Enterprise Value | -0.08B | PEG | - | EPS next Q | -2.39 | Inst Own | 56.63% | Short Float | 17.21% | Perf Quarter | -47.25% |
| Income | -0.16B | P/S | 3.11 | EPS this Y | 32.89% | Inst Trans | 9.44% | Short Ratio | 4.54 | Perf Half Y | -59.16% |
| Sales | 0.03B | P/B | 0.4 | EPS next 5Y | 36.41% | ROA | -72.34% | Short Interest | 2.94M | Perf YTD | -66.2% |
| Book/sh | 13.24 | P/C | 0.51 | EPS past 3/5Y | 93.94% 86.72% | ROE | -81.82% | 52W High | -74.32% ($20.56) | Perf Year | -71.57% |
| Cash/sh | 10.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -71.5% | 52W Low | 5.39% ($5.01) | Perf 3Y | -99.7% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 98.71% | Gross Margin | 76.53% | Volatility(W/M) | 5.68% 7.99% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -2.9 | Sales Y/Y TTM | 196.02% | Oper. Margin | -568.43% | ATR (14) | 0.49 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 6.46 | EPS Q/Q | 36.82% | Profit Margin | -548.64% | RSI (14) | 18.52 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.61 | Sales Q/Q | 577.88% | SMA20 | -16.86% ($6.35) | Beta | 1.84 | Target Price | $39 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/11/9 | SMA50 | -45.45% ($9.68) | Rel Volume | 0.96 | Prev Close | $5.37 |
| Employees | 142 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 7.66% 75.38% | SMA200 | -57.86% ($12.53) | Avg Volume(3M) | 0.65M | Price | $5.28 |
| IPO | 2012/2/3 | Option/Short | Yes/Yes | Trades | 4657 | Volume | 619,611 | Change | -1.68% |
💊 Tonix Pharmaceuticals (ticker: TNXP) is a U.S. biotech company targeting central nervous system disorders as well as immune and infectious disease areas. It is a small-cap pharmaceutical company attempting to transition from the clinical stage to commercialization, with its fibromyalgia treatment Tonmya receiving FDA approval. Stock price movements are largely driven by progress in its new drug pipeline.
Over the past 1 year, on the lower side
74% below its 1-year high.
Traded about as much as usual. That is 96% of its average volume.
Next earnings report: November 9
10 days to go.
TNXP has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +32.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $311. Peers typically go for $1,089.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 56.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #371 of 594 in the industry
Based on market cap of $91M.
PLYX#369 Polaryx Therapeutics Inc $93M PER - 
TNYA#370 Tenaya Therapeutics Inc $91M PER - TNXP#371 Tonix Pharmaceuticals Holding Corp $91M PER - 
EQ#372 Equillium Inc $90M PER - 
NTHI#373 NeOnc Technologies Holdings Inc $90M PER - 
FAQ
What kind of company is TNXP?
TNXP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TNXP?
The market cap of TNXP is approximately $91M, ranking 4,531 within its sector.
What is the 52-week high and low for TNXP?
TNXP has recorded a 52-week high of $20.56 and a low of $5.01.
